Lesinurad (Zurampic)


FDA Approved Indication:
  • Indicated in combination with a xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone
Prior authorization criteria:
  • Diagnosis of hyperuricemia associated with gout, AND
  • Despite trying and failing first-line agents, patient still has symptomatic hyperuricemia, AND
  • Will be used as combination therapy with a xanthine oxidase inhibitor (i.e., allopurinol or Uloric [febuxostat]), AND
  • Patient does not have any of the following: severe renal impairment (eCLcr < 45 mL/min), end stage renal disease, is a recipient of a kidney transplant, is on dialysis, or has severe (Child-Pugh class C) hepatic impairment, AND
  • Contraindicated for use in tumor lysis syndrome or Lesch-Nyhan syndrome where the rate of uric acid formation is greatly increased
  • 200 mg once daily in combination a xanthine oxidase inhibitor
  • 1 year
WHA is closely monitoring the Coronavirus Disease 2019 (COVID-19). Learn more about COVID-19.